Clinical trial
Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes
NCT00106808 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00106808 |
|---|---|
| Title | Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes |
| Official title | A Phase 3, Randomized, Double-blind, Active Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar (BMS-298585) Compared to Pioglitazone in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Muraglitazar, Pioglitazone |
| Enrollment | 1,440 |
| Start date | Aug 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Apr 1, 2005 |
| Last update posted | Sep 14, 2010 |
| Countries | Argentina, Australia, Brazil, Canada, Chile, India, Mexico, Peru, Philippines, Russia, Taiwan, Thailand and 2 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: